The purpose of the bridge loan is to strengthen Klaria's financial flexibility during the ongoing process that the Company is conducting together with BDO London to access all available markets around the world.  Klaria would also like to highlight that the preparatory activities ahead of CNX Therapeutics' expected launch of Sumatriptan Alginate Film in Europe are progressing according to plan, including ongoing large-scale manufacturing of the product. In addition, the market for migraine treatment continues to grow, and Klaria believes that the Company's product has a good opportunity to take a very strong position in the treatment of acute migraine - completely replacing many of the existing sumatriptan products.

"This financing significantly strengthens our flexibility, thus creating stability during the process we are now conducting together with BDO. At the same time, we continue to progress towards the market launch of Sumatriptan Alginate Film in Europe together with our licensing partner CNX Therapeutics. The product's unique advantages in the form of an overall lower dose and rapid and reliable delivery of the sumatriptan to the bloodstream with much lower variability mean that we see the perfect conditions to establish a very strong penetration in the large and growing worldwide market for acute migraine treatment," says Klaria's Chairman of the Board Fredrik Hübinette.

The bridge loan will be disbursed immediately and runs up until May 27 2027. The loan has an arrangement fee of 1,5 MSEK, and a fixed interest rate for the loan period of 30-day Stibor +1.5 percentage points.